Biotech Co.** | Pharma Co. (Symbol/Country) | Type/Product Area | Amount | Terms/Details (Date) |
I. MODIFIED AGREEMENTS | ||||
Affymetrix Inc. |
Pfizer Inc. (NYSE:PFE) | Pfizer entered EasyAccess Silver Agreement, under which it gains preferential access to Affymetrix's standard and custom GeneChip arrays, instrumentation and software to monitor gene expression; original agreement signed 7/97 | ND | Package offers volume discount pricing (3/99) |
Corvas International Inc. | Schering-Plough Corp. (NYSE:SGP) | Extension of 5/98 alliance to develop orally available inhibitors of a key protease thought to be involved in hepatitis C virus replication | $1.6M | ND (5/99) |
Digital Gene Technologies Inc.* | Immunex Corp. | Immunex exercised right to renew experimentation license on a molecule implicated in the disease mechanism for inflammatory bowel disease; agreement signed 12/97 | Agreement calls for annual renewal rights and fee payment for experimentation licenses issued for each gene chosen for study by Immunex researchers (6/99) | |
Enzon Inc. | Schering-Plough Corp. (NYSE:SGP) | Companies amended 11/90 agreement for PEG-Intron, a pegylated version of Schering-Plough 's Intron A (recombinant interferon alfa2b); Schering-Plough also gains license to another form of pegylation technololgy, dubbed "branched PEG" | Schering-Plough will pay royalties on sales at a higher effective rate in exchange for return to Schering-Plough of Enzon's exclusive U.S. manufacturing rights to PEG-Intron; Enzon also granted Schering-Plough a non-exclusive worldwide license, with limited rights to sublicense "branched" pegylation technology (6/99) | |
Incyte Pharmaceuticals Inc. | AstraZeneca Group plc (U.K.; NYSE:AZN) | Companies reached agreement on general terms of expansion and extension of 6/96 database agreement between Incyte and Zeneca Ltd., with expanded deal to include access to LifeSeq Gold assembled database, ZooSeq animal model database, and access to additional genomic databases and services | Original agreement called for annual subscription fees, plus milestones and royalties for products based on the information; new terms were ND (6/99) | |
Incyte Pharmaceuticals Inc. | F. Hoffmann-La Roche Ltd. (Switzerland) | Expansion and extension of 4/96 agreement, providing Roche access to Incyte's LifeSeq Gold database, the ZooSeq animal model database, and continued access to the LifeSeq Atlas mapping database | ND | Roche will pay annual access fees; Incyte could receive future milestone payments and royalties on sales of products developed with Incyte technology and database information (6/99) |
NV Organon (unit of Akzo Nobel; the Netherlands) | Expansion of 10/97 agreement, providing Organon access to Incyte's LifeSeq Gold database and data from its GEM microarray technology | ND | Organon will pay annual access and per-array fees; Incyte could receive future milestone payments and royalties on sales of products developed with Incyte technology and database information (6/99) | |
Medarex Inc. | Schering AG (Germany) | Amendment to 2/98 development agreement under which Medarex will use its HuMAb-Mouse technology to produce fully human antibodies to three new proprietary antigens for Schering | ND | Medarex could receive additional license fees, milestone payments and royalties on future product sales (5/99) |
Mitotix Inc.* | Cell Genesys Inc. | In 4/98, Cell Genesys licensed from Mitotix a series of cell-cycle inhibitor genes for use in cardiovascular applications; new agreement expands domain to cancer | Cell Genesys intends to seek a pharmaceutical partner to commercialize potential products based on p27/p26 gene therapy, with revenue being shared with Mitotix; additional terms ND (4/99) | |
Molecumetics Ltd. (a subsidiary of Tredegar Industries; NYSE:TG) | Asahi Chemical Industry Co. Ltd. (Tokyo) | R&D collaboration replacing 5/97 collaboration agreement using Molecumetics' SMART Library technology for discovery and development of small-molecule drugs for various therapies | ND | Molecumetics will receive research funding, milestone payments based on clinical progress of the compounds, and royalties on sales of products from the program; Asahi will have exclusive development and sales rights in Japan and other Asian countries (4/99) |
Neurogen Corp. | Pfizer Inc. (NYSE:PFE) | 2nd extension of 11/95collaboration to develop drugs that block the neuropeptide Y (NPY) neurotransmitter for the treatment of obesity; the 1-year extension will fund continued research with the goal of discovering multiple novel drug candidates | ND | Original $60M agreement included equity, milestones and research funding; details of 1-year extension ND (5/99) |
Neurogen Corp. | Pfizer Inc. (NYSE:PFE) | Neurogen licensed its integrated drug discovery technology, Accelerated Intelligent Drug Discovery, to long-time partner Pfizer (companies signed their first agreement 2/92) | $27M | Pfizer paid $3M up front and and will pay an additional $18M by the end of 2000 as AIDD is installed; the final $9M will come as Neurogen makes system enhancements to customize the technologyto Pfizer's needs (6/99) |
Nexell Therapeutics Inc. (formerly Vimrx Pharmaceuticals Inc.) | Baxter Healthcare Corp. (NYSE:BAX) | Companies restructured 6/97 agreement for commercialization of the Isolex stem-cell selection device (approved by the FDA 6/99), with Baxter agreeing to provide additional financial support; parties also agreed to terminate earlier marketing, sales and distribution agreement, and transfer related assets to Nexell to enable Nexell to assume those responsibilities directly |
$20M | Baxter will provide either a a $20M line of credit or help support and complete a larger private placement financing; as part of new marketing arrangement, certain Baxter sales and marketing personnel will be offered jobs with Nexell; Baxter will continue to provide contract manufacturing, physical distribution, instrument placement and service, and related functions under a new services agreement (5/99) |
OSI Pharmaceuticals Inc | Pfizer Inc. (NYSE:PFE) | License agreement for OSI to develop small-molecule inhibitors licensed from Pfizer for treatment of mild to moderate psoriasis; compounds are the product of the companies' ongoing cancer collaboration initiated 7/88 | ND | OSI could receive up-front fees, reimbursement of clinical development costs, milestone payments and royalties on product sales if Pfizer exercises its option for full clinical development and marketing (5/99 |
Pfizer Inc. (NYSE:PFE) | Expansion of 4/96 collaboration agreement in Anaderm Research Corp.; OSI will continue to functionas drug-discovery and preclinical development arm of Anaderm, providing assay biology, high-throughput screening, compound libraries, combinatorial, medicinal, and natural-product chemistry, as well as pharmaceutics, pharmacokinetics and molecular biology for development of cosmeceuticals for use in certain cosmetic and quality-of-life indications such as skin pigmentation, wrinkling and hair loss | $50M | OSI could receive up to $50M in total payments over a 6-year period, as well as royalties on sales of successful products (5/99 | |
Pharmacyclics Inc. | Alcon Pharmaceuticals Ltd. (subsidiary of Nestle SA; Switzerland | Alcon committed to further evaluation and development of light-activated drug, lutetium texaphyrin, in the fieldof ophthalmology; companies entered evaluation and license agreement 12/97 | Pharmacyclics received additional payment and may receive further payments based upon successful completion of milestones, as well as royalties (4/99) | |
Powderject Pharmaceuticals plc (U.K.) | Glaxo Wellcome plc. (U.K.; NYSE: GLX) | Second expansion of 3/98 agreement to develop and commercialize up to 11 powdered DNA vaccines; Glaxo has purchased 2 additional DNA vaccine licenses for HIV therapy and one undisclosed infectious disease field, and has renewed all of its option rights under the agreement | $3.4M | PowderJect received new license and option fees of $3.4M (6/99) |
Signal Pharmaceuticals Inc.* | Ares Serono (Switzerland) | Expansion of 12/97 collaboration to identify small-molecule inhibitors of the NF-kB pathway | $2M | Expansion gives Ares Serono exclusive rights to certain Asian countries, including Japan, that were not covered in the original; Signal will receive a $2M license fee and potential milestones and royalties (5/99) |
II. TERMINATED AGREEMENTS | ||||
Amrad Corp. Ltd. (Australia; ASX:AML) | SmithKline Beecham plc (NYSE:SBH) | SmithKline decided against exercising an option to acquire a license to the AM94 rotavirus vaccine; original agreement signed 4/98 | SmithKline's decision was based on initial immune response data from a clinical trial in Australia that did not provide clear efficacy data (6/99) | |
AutoImmune Inc. |
Eli Lilly & Co. (NYSE:LLY) | Restructuring of 12/94 development agreement for AI-401 oral diabetes product | ND | Lilly will receive a non-exclusive research license to complete 4 current, separate studies of AI-401; Lilly will continue to provide AutoImmune with full access to the clinical results upon completion of the studies, including the right to use the data for any reason; AutoImmune will regain rights to the product and the underlying technology, and will receive no milestone payments (4/99) |
Cadus Pharmaceutical Corp. | Bristol-Myers Squibb Co. (NYSE:BMY) | R&D collaboration signed 7/94 expired; research used Cadus' yeast-based screening technologies, primarily in an effort to find drugs aimed at G-protein-coupled receptors and related cell-signaling pathways | Agreement, originally for 3 years and up to $45M, was renewed in 1997, and then allowed to expire; Cadus received in excess of $40M during the relationship and has delivered compounds to Bristol-Myers (4/99) | |
Cytogen Corp. | Faulding Inc. (unit of F.H. Faulding & Co. Ltd.; Australia) | Cytogen regained Canadian marketing rights to ProstaScint and OncoScint (both are cancer diagnostics OncoScint is approved in Canada and ProstaScint is under review there); move stemmed from shift in strategic direction at Faulding; original agreement signed 3/99 | ND | Cytogen said no costs were incurred in regaining rights (6/99) |
Berlex Laboratories Inc. (subsidiary of Schering AG; Germany) | Cytogen regained Canadian marketing rights to Quadramet, approved in Canada for metastatic bone pain; original agreement signed 10/98 | ND | Cytogen said no costs were incurred in regaining rights (6/99) | |
CytoTherapeutics Inc. | AstraZeneca Group plc (U.K.) | R&D collaboration signed in 3/95 with Astra AB covered encapsulated bovine cell implant for the treatment of severe, chronic pain in cancer patients | Following analysis of Phase II trial results, in which results failed to meet AstraZeneca's criteria for continuation of trials, AstraZeneca terminated the collaboration (6/99) | |
DepoMed Inc. (AMEX:DMI) | Bristol-Myers Squibb Co. (NYSE:BMY) | Bristol-Myers will not exercise a 6/96 license and development option to use DepoMed's Gastric Retention System for an undisclosed pharmaceutical product | ND | ND (4/99) |
NeuroSearch | Bristol-Myers Squibb Co. (NYSE:BMY) | Cancellation of 12/95 collaboration agreement on joint development of NeuroSearch's anti-Parkinson's drug, brasofensine | ND | NeuroSearch will retain all upfront and milestone payments; Bristol-Myers will transfer all scientific and commercial rights, as well as all rights to the results of the studies (6/99) |
Scios Inc. | Bayer AG (Germany) | Commercialization agreement signed 5/98 for Scios' congestive heart failure drug, Natrecor (nesiritide); the drug is a recombinant version of the human hormone b-type natriuretic peptide b-type natriuretic peptide | Following the FDA's rejection of NDA, Bayer withdrew from deal, which had included a $20M up-front fee, plus a possible $40M in milestones; Scios is designing a new clinical trial and looking for a new partner (6/99) | |
Sepracor Inc. | Johnson & Johnson (NYSE:JNJ) | J&J elected not to exercise option to co-promote norastemizole, a nonsedating antihistamine in Phase III trials | ND | Sepracor has worldwide rights to J&J intellectual property covering norastemizole; J&J will receive a royalty on norastemizole sales; companies' partnership on norcisapride unchanged (5/99) |
NOTES: | ||||
# This chart does not include any marketing and/or distribution agreements that involve agricultural product development. The information in the chart covers the time period between 3/24/99 and 6/31/99. | ||||
ND = Not disclosed, reported and/or available; NYSE=New York Stock Exchange; ASX=Australian Stock Exchange | ||||
* Private companies are indicated with an asterisk. | ||||
** Unless otherwise noted, the trading symbols for public biotechnology companies can be found by referring to the BioWorld Stock Report For Public Biotechnology Companies on pp. 14 - 15. | ||||
To read more on related topics, click on one of the words below.